Respirology (Carlton, Vic.) · 2025
Bronchoalveolar Lavage Lymphocytosis and Early Glucocorticoid Response: A Prospective Study of 150 Subjects With Interstitial Lung Disease.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dhooria Sahajal, Rao Harshith, Gupta Nalini, Sehgal Inderpaul Singh, Agarwal Ritesh, Prasad Kuruswamy Thurai, Muthu Valliappan, Garg Mandeep, Bal Amanjit, Aggarwal Ashutosh Nath
Аннотация
BACKGROUND AND OBJECTIVE: Bronchoalveolar lavage lymphocyte percentage (BLP) is considered a prognostic marker for interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF). Its association with an early glucocorticoid response (EGR) has not been studied systematically. We aimed to assess the association of BLP and other factors with EGR.
METHODS: We prospectively enrolled subjects with non-IPF ILDs and treated them with glucocorticoids. We defined EGR as a composite response in symptoms and pulmonary function tests 2 months after glucocorticoid initiation. Cases were those with EGR (responders), while non-responders (without EGR) formed the controls. The primary exposure was the BLP expressed on an ordinal scale: 0%-19%, 20%-29%, 30%-39%, ≥ 40%. Confounders included age, sex, body mass index, smoke exposure, %pred FVC, symptom duration, inflammatory and/or fibrotic phenotype on chest computed tomography. We also assessed factors associated with progressive disease at 6 months.
RESULTS: We included 150 subjects (mean age, 51.2 years; 39% men); 73% had either hypersensitivity pneumonitis or connective tissue disease-related ILD. One hundred and thirty-one subjects (69 responders; 62 non-responders) followed up at 2 months. The BLP (adjusted odds ratio [aOR], 1.64; 95% confidence intervals [CI], 1.03-2.63; p = 0.04) and symptom duration (aOR, 0.60; 95% CI, 0.40-0.92; p = 0.02) were independently associated with EGR. A BLP < 20% (aOR, 4.37; 95% CI, 1.37-13.96; p = 0.01) and history of smoke exposure (aOR, 4.59; 95% CI, 1.25-16.91; p = 0.02) independently predicted progressive disease at 6 months.
CONCLUSION: Higher BLPs and shorter symptom duration were associated with EGR, while BLP < 20% and smoke exposure predicted progressive disease despite glucocorticoid treatment.
METHODS: We prospectively enrolled subjects with non-IPF ILDs and treated them with glucocorticoids. We defined EGR as a composite response in symptoms and pulmonary function tests 2 months after glucocorticoid initiation. Cases were those with EGR (responders), while non-responders (without EGR) formed the controls. The primary exposure was the BLP expressed on an ordinal scale: 0%-19%, 20%-29%, 30%-39%, ≥ 40%. Confounders included age, sex, body mass index, smoke exposure, %pred FVC, symptom duration, inflammatory and/or fibrotic phenotype on chest computed tomography. We also assessed factors associated with progressive disease at 6 months.
RESULTS: We included 150 subjects (mean age, 51.2 years; 39% men); 73% had either hypersensitivity pneumonitis or connective tissue disease-related ILD. One hundred and thirty-one subjects (69 responders; 62 non-responders) followed up at 2 months. The BLP (adjusted odds ratio [aOR], 1.64; 95% confidence intervals [CI], 1.03-2.63; p = 0.04) and symptom duration (aOR, 0.60; 95% CI, 0.40-0.92; p = 0.02) were independently associated with EGR. A BLP < 20% (aOR, 4.37; 95% CI, 1.37-13.96; p = 0.01) and history of smoke exposure (aOR, 4.59; 95% CI, 1.25-16.91; p = 0.02) independently predicted progressive disease at 6 months.
CONCLUSION: Higher BLPs and shorter symptom duration were associated with EGR, while BLP < 20% and smoke exposure predicted progressive disease despite glucocorticoid treatment.